Docket #: 524-099

Precision Immunotherapy: AIPowered Biomarkers for Predicting Outcomes in Advanced Esophagogastric Cancer

Stanford researchers have developed an innovative Al-driven solution for predicting immunotherapy response in esophagogastric cancer patients. By leveraging deep learning models and single-cell analysis, this method identifies robust biomarkers associated with treatment outcomes.

Esophagogastric cancer is the second leading cause of cancer-related deaths globally, posing a significant health concern. While immunotherapy with immune checkpoint inhibitors (ICIs) is the standard of care and has shown remarkable efficacy, its benefits vary widely among patients. Many patients fail to experience benefits from these expensive treatments, highlighting the urgent need for reliable predictive biomarkers. Existing biomarker tests like PD-L1 immunohistochemistry suffer from inaccuracies and high variability, leaving patients to endure ineffective treatments, toxic side effects, and financial strain. This discrepancy underscores a critical challenge and highlights a urgent need for reliable biomarkers for predicting immunotherapy treatment response.

To address this problem, Stanford researchers have developed an innovative Aldriven solution for predicting immunotherapy response in esophagogastric cancer patients. By conducting single-cell analysis of standard histopathology images from immune checkpoint inhibitor-treated patients, this methodology accurately forecasts treatment outcomes. By leveraging deep learning models and fully automated cell annotation, this approach provides a comprehensive analysis of the tumor microenvironment, including cell density, composition, and spatial interactions, thereby identifying robust biomarkers associated with treatment outcomes. In a

study of 82 advanced esophagogastric cancer patients, this approach demonstrated significant predictive power, highlighting its potential for personalized cancer treatment. In summary, this innovation represents a transformative leap in immunotherapy selection, offering personalized treatments for patients suffering from cancer.

Stage of Development:

Software Prototype. Next steps include extracting additional types of spatial features from H&E images, which will provide a deeper insight into tumor microenvironment with refined cellular resolution. This will achieve further improvements in accuracy for predicting immunotherapy outcomes.

Applications

- Discovery of reliable biomarkers for predicting patient response to immunotherapy
- Selecting the right patients that will benefit from specific immunotherapies
- Guides immunotherapy treatment decisions for clinicians and improves patient outcomes
- Significant cost effectiveness from selecting the right patients for immunotherapy
- Optimization of patient selection in clinical trials
- Biomarker-directed treatment strategies
- Improves cancer survival outcomes by avoiding ineffective and toxic therapies
- Companion diagnostics in cancer immunotherapy

Advantages

- Significantly improves upon existing immunotherapy predictive biomarkers
- Utilizes standard diagnostic histopathology slides for increased accessibility and cost-effectiveness
- Single-cell spatial analysis approach provides high-resolution biologically interpretable insights into the tumor microenvironment at the cellular level using H&E slides
- Computational approach provides deeper insights into tumor microenvironment

- Avoids overfitting and generalizable, unlike existing black box models
- Mitigates ineffective treatments and reduces toxicity risks
- Alleviates financial burdens for immunotherapy treated patients

Innovators

• Ruijiang Li

Licensing Contact

Eileen Lee

Email